
Axsome Therapeutics, Inc. (NASDAQ:AXSM) reported better-than-expected second-quarter financial results on Monday.
Axsome Therapeutics reported quarterly losses of 47 cents per share compared to analyst consensus estimate of losses of $1.07 per share. The company reported quarterly sales of $150.04 million which beat the analyst consensus estimate of $140.33 million.